Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Please fill in all required fields marked with (*)

By submitting this registration form I confirm that I have read and agree to the Terms of Use and the Privacy Notice below.

PRIVACY NOTICE

We will use the personal data you provide above to register you and provide you with access to the DUPIXENT Portal. Sanofi will process your personal data on the basis that it is necessary for our legitimate interests (for provision of administration and IT services and network security, to keep our website updated and relevant, to study how customers use our products/services and to develop our business). Aventis Pharma Limited is the controller and responsible for your personal data. Please see our Privacy Policy for more detailed information about our data processing activities.

If you tick the box above to receive emails from Sanofi, we will also use your personal data to send you information by email about goods and services which we feel may be of interest to you on the basis that it is necessary for our legitimate interests (to develop our products/services and grow our business). For more details specifically about how we use your data to send you these emails, please see our separate Staying in Touch Privacy Notice.

AD, atopic dermatitis.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: July 2020.